{
  "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5",
  "docSlug": "225408061c3ed04b028031d27cf2467f",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides",
  "authorId": "immix-biopharma",
  "authorName": "ImmixBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 62,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a visual timeline comparison to highlight the clinical advantage of NXC-201's shorter side-effect profile.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/17",
  "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5",
  "deckJsonHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5.json",
  "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.8,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Comparative clinical timeline charts for NXC-201, Carvykti, and Abecma",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "191fd300-de08-4ddb-8e96-0f4f13cca0a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.15,
        "x": 0.85,
        "y": 0.15
      },
      "kind": "list",
      "text": "1. NXC-201: Max 7-day CRS; Others: up to 63 day CRS. 2. NXC-201: Low (4%) Neurotoxicity; Others: Up to 578-day neurotoxicity. 3. NXC-201: sBCMA reduced in ~30 days; Others: sBCMA reduced in ~60-155 days. 4. NXC-201: CAR-T cells exit body after sBCMA reduced; Others: CAR-T cells remain elevated.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b773ddc-eeca-4072-aff1-4487c53e6776",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.96,
        "x": 0.02,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "NXC-201: No measurements available beyond 30 days in multiple myeloma as of the Feb 2023 data cutoff...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9435c02-1cf2-4366-8c8f-7d93044dc9a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "N-GENIUS Technology Platform – NXC-201: First “Single-Day CRS” CAR-T – Narrow, Predictable Side Effect Window in Multiple Myeloma (1/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f2115ea-e610-48a5-91ea-0fda738d2264",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before/after framing",
      "slug": "before-after-framing",
      "agent": null,
      "layer": "slide",
      "matchId": "3522f845-2639-46fb-8428-0b67eca79172",
      "evidence": "NXC-201: Max 7-day CRS; Others: up to 63 day CRS",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "d4656b96-1e2e-4709-83c7-ec38c2ce7ec3",
      "evidence": "Direct visual comparison of clinical trial outcomes across three products.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 34,
      "from": 15,
      "beatId": "167b9d6c-4f69-438b-b991-0f1839680299",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}